The genomic-level similarity between the AMPC and NEPC tumors in our study was surprising, with only the loss of RB1 in the metastatic brain NEPC (as compared to the primary prostate and dural adenocarcinoma) being the most obvious genomic feature that could have predicted further transition from AMPC to a neuroendocrine carcinoma. The gene discussed is RB1; the disease is neuroendocrine carcinoma.